Skip to content
Review Open access

Revisiting the Interferon Axis in Systemic and Cutaneous Lupus Erythematosus: From Targeted Therapy to Real-World Clinical Practice.

Sep 2026 · Archives of Rheumatology · 0 citations · 82 references
Medicine

TL;DR

This review article revisits the IFN-I axis in SLE and cutaneous lupus erythematosus, with special emphasis on its targeted therapies.

Abstract

For many years, systemic lupus erythematosus (SLE) pathogenesis was interpreted primarily through the lens of adaptive immunity, with emphasis on disruption of T- and B-cell tolerance, autoantibody production, immune-complex deposition, and complement activation. However, a major shift in the understanding of SLE immunopathogenesis has been the recognition that innate immune activation, and particularly the type I interferon (IFN-I) axis, provides a mechanistic link between acid sensing, antiviral-like immune activation, and tissue inflammation. While several approaches have demonstrated biological activity and provided proof-of-concept for therapeutic modulation of the IFN-I pathway, anifrolumab, a monoclonal antibody targeting IFNAR1, currently represents the most clinically validated strategy and the only approved IFN-I-targeted therapy for SLE, based on its efficacy in phase III trials. In this review article, we revisit the IFN-I axis in SLE and cutaneous lupus erythematosus, with special emphasis on its targeted therapies.

Read PDF

Similar papers

Review Open access Oct 2026

Therapeutic Strategies Targeting Immune Dysregulation in Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease driven by loss of immune tolerance, dysregulated nucleic acid sensing and cytokine signaling, abnormal B- and T-cell activation, persistent autoantibody production, and impaired clearance of immune cells and debris. These interconnected abnormalit...

Yu-Rin Kim, E. Yeo, I. Kang · 0 citations
Review Open access Sep 2026

SYSTEMIC LUPUS ERYTHEMATOSUS – PAST, PRESENT AND EMERGING THERAPIES

Background Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by immune dysregulation, autoantibody production, and immune complex-mediated tissue damage. Despite advances in disease management, SLE remains associated with substantial morbidity, increased mortality, and signif...

Jakub Zwardoń, Aleksandra Suchołbiak, Miłosz Rewekant et al. · 0 citations
Review Open access Sep 2026

B-CELL-TARGETED THERAPIES IN THE TREATMENT OF AUTOIMMUNE SKIN DISEASES – A COMPREHENSIVE REVIEW OF MECHANISMS, EFFICACY, AND FUTURE DIRECTIONS

Autoimmune skin diseases (AISDs) constitute a complex group of conditions whose pathogenesis is based on abnormal activation of the immune system, leading to the production of autoantibodies and damage to skin structures. In recent years, a key role in these processes has been attributed to B lymphocytes, which not onl...

Patryk Brzezicki, Natalia Bębenek, Gabriela Barszcz et al. · 0 citations
Review Open access Sep 2026

Assessing the role of interferons in congenital and acquired interferonopathies: a review

Impaired interferon (IFN) production plays a key role in the pathogenesis of a wide range of autoimmune diseases (AIDs), such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), dermatomyositis, and others. This review examines both the physiological functions of IFNs under normal conditions (antiviral defe...

T. Ospelnikova, A. D. Shitova, O. N. Egorova et al. · 0 citations
Review Open access Oct 2026

Comparative efficacy and safety of B-cell-targeted biologics in systemic lupus erythematosus: a systematic review and network meta-analysis

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement and heterogeneous clinical manifestations. Aberrant B-cell activation and elevated levels of B-lymphocyte stimulator (BLyS) play a central role in its pathogenesis [1]. Several B-cell–targeted biologic agents hav...

Bing-Bing Deng, Zhi-Hang Xiao, Hong-Ru Wang et al. · 0 citations
Review Open access Oct 2026

Interferon Signature Genes in Early Diagnosis of Systemic Lupus Erythematosus: Current Value and Limitations

Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease, and early diagnosis remains a major clinical challenge. Abnormal activation of the type I interferon (IFN) pathway is one of the core mechanisms in the pathogenesis of SLE. The IFN signature, as a biomarker reflecting activation of this pa...

Ting Chen · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.